Nabriva Therapeutics plc Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2017 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Nabriva Therapeutics plc quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2017 to Q1 2023.
  • Nabriva Therapeutics plc Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2023 was -$4.85M, a 321% decline year-over-year.
  • Nabriva Therapeutics plc annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.85M, a 97.2% decline from 2021.
  • Nabriva Therapeutics plc annual Net Cash Provided by (Used in) Financing Activities for 2021 was $66.4M, a 146% increase from 2020.
  • Nabriva Therapeutics plc annual Net Cash Provided by (Used in) Financing Activities for 2020 was $26.9M, a 52% decline from 2019.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$4.85M -$7.05M -321% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-22
Q1 2022 $2.19M -$32.7M -93.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q1 2021 $34.9M +$65.1M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 -$30.2M -$39.9M -412% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 $9.68M -$9.38M -49.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 $19.1M +$20.2M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q1 2017 -$1.17M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.